{"id":477191,"date":"2020-04-01T13:10:02","date_gmt":"2020-04-01T13:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477191"},"modified":"2020-04-01T13:10:02","modified_gmt":"2020-04-01T13:10:02","slug":"lupus-nephritis-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lupus-nephritis-epidemiology-forecast-to-2030_477191.html","title":{"rendered":"Lupus Nephritis Epidemiology Forecast to 2030"},"content":{"rendered":"
\"Lupus<\/a><\/div>\n

 <\/p>\n

DelveInsight has launched a new report on Lupus Nephritis Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s ‘Lupus Nephritis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Lupus Nephritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

Lupus nephritis<\/strong> (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE<\/strong>. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.<\/p>\n

Systemic lupus erythematosus(SLE)<\/strong> is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is being characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE include inflammation, vasculitis, immune complex deposition, and vasculopathy.<\/p>\n

\"\"<\/p>\n

 <\/p>\n

Request for :- <\/strong><\/em>Epidemiology forecast 2030<\/a><\/p>\n

Lupus Nephritis Epidemiology Perspective by DelveInsight<\/strong><\/p>\n

The Lupus Nephritis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Lupus Nephritis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Lupus Nephritis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.<\/p>\n

 <\/p>\n

Lupus Nephritis Detailed Epidemiology Segmentation<\/strong><\/p>\n

The Lupus Nephritis epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.<\/p>\n

The DelveInsight Lupus Nephritis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.<\/p>\n

Report Key facts:-<\/strong><\/em><\/p>\n

1. As per DelveInsight’s estimates, total Prevalent population of Lupus Nephritis in the 7 major markets was190,819 in 2017 <\/p>\n

2. According to DelveInsight’s analysis<\/em><\/strong>, the United Sates accounted for the maximum number of LN patients with 134,190<\/strong>cases in 2017 followed by Italy with 17,013 <\/strong>cases<\/p>\n

3. DelveInsight estimates, <\/em><\/strong>in 2017, Proteinuria associated with LN cases were found in all of the diagnosed cases, while second common manifestation in LN was microscopic hematuria with 85,882 cases(80%).<\/p>\n

Report Highlights<\/strong><\/p>\n